Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary
© 2020 American Association of Clinical Endocrinologists. Published by Elsevier, Inc. All rights reserved..
The treatment of lipid disorders begins with lifestyle therapy to improve nutrition, physical activity, weight, and other factors that affect lipids. Secondary causes of lipid disorders should be addressed, and pharmacologic therapy initiated based on a patient's risk for atherosclerotic cardiovascular disease (ASCVD). Patients at extreme ASCVD risk should be treated with high-intensity statin therapy to achieve a goal low-density lipoprotein cholesterol (LDL-C) of <55 mg/dL, and those at very high ASCVD risk should be treated to achieve LDL-C <70 mg/dL. Treatment for moderate and high ASCVD risk patients may begin with a moderate-intensity statin to achieve an LDL-C <100 mg/dL, while the LDL-C goal is <130 mg/dL for those at low risk. In all cases, treatment should be intensified, including the addition of other LDL-C-lowering agents (i.e., proprotein convertase subtilisin/kexin type 9 inhibitors, ezetimibe, colesevelam, or bempedoic acid) as needed to achieve treatment goals. When targeting triglyceride levels, the desirable goal is <150 mg/dL. Statin therapy should be combined with a fibrate, prescription-grade omega-3 fatty acid, and/or niacin to reduce triglycerides in all patients with triglycerides ≥500 mg/dL, and icosapent ethyl should be added to a statin in any patient with established ASCVD or diabetes with ≥2 ASCVD risk factors and triglycerides between 135 and 499 mg/dL to prevent ASCVD events. Management of additional risk factors such as elevated lipoprotein(a) and statin intolerance is also described.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists - 26(2020), 10 vom: 01. Okt., Seite 1196-1224 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Handelsman, Yehuda [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticholesteremic Agents |
|---|
| Anmerkungen: |
Date Completed 22.01.2021 Date Revised 22.01.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.4158/CS-2020-0490 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320340929 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320340929 | ||
| 003 | DE-627 | ||
| 005 | 20231225173352.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4158/CS-2020-0490 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1067.xml |
| 035 | |a (DE-627)NLM320340929 | ||
| 035 | |a (NLM)33471721 | ||
| 035 | |a (PII)S1530-891X(20)48204-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Handelsman, Yehuda |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.01.2021 | ||
| 500 | |a Date Revised 22.01.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 American Association of Clinical Endocrinologists. Published by Elsevier, Inc. All rights reserved. | ||
| 520 | |a The treatment of lipid disorders begins with lifestyle therapy to improve nutrition, physical activity, weight, and other factors that affect lipids. Secondary causes of lipid disorders should be addressed, and pharmacologic therapy initiated based on a patient's risk for atherosclerotic cardiovascular disease (ASCVD). Patients at extreme ASCVD risk should be treated with high-intensity statin therapy to achieve a goal low-density lipoprotein cholesterol (LDL-C) of <55 mg/dL, and those at very high ASCVD risk should be treated to achieve LDL-C <70 mg/dL. Treatment for moderate and high ASCVD risk patients may begin with a moderate-intensity statin to achieve an LDL-C <100 mg/dL, while the LDL-C goal is <130 mg/dL for those at low risk. In all cases, treatment should be intensified, including the addition of other LDL-C-lowering agents (i.e., proprotein convertase subtilisin/kexin type 9 inhibitors, ezetimibe, colesevelam, or bempedoic acid) as needed to achieve treatment goals. When targeting triglyceride levels, the desirable goal is <150 mg/dL. Statin therapy should be combined with a fibrate, prescription-grade omega-3 fatty acid, and/or niacin to reduce triglycerides in all patients with triglycerides ≥500 mg/dL, and icosapent ethyl should be added to a statin in any patient with established ASCVD or diabetes with ≥2 ASCVD risk factors and triglycerides between 135 and 499 mg/dL to prevent ASCVD events. Management of additional risk factors such as elevated lipoprotein(a) and statin intolerance is also described | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Anticholesteremic Agents |2 NLM | |
| 650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
| 700 | 1 | |a Jellinger, Paul S |e verfasserin |4 aut | |
| 700 | 1 | |a Guerin, Chris K |e verfasserin |4 aut | |
| 700 | 1 | |a Bloomgarden, Zachary T |e verfasserin |4 aut | |
| 700 | 1 | |a Brinton, Eliot A |e verfasserin |4 aut | |
| 700 | 1 | |a Budoff, Matthew J |e verfasserin |4 aut | |
| 700 | 1 | |a Davidson, Michael H |e verfasserin |4 aut | |
| 700 | 1 | |a Einhorn, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Fazio, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Fonseca, Vivian A |e verfasserin |4 aut | |
| 700 | 1 | |a Garber, Alan J |e verfasserin |4 aut | |
| 700 | 1 | |a Grunberger, George |e verfasserin |4 aut | |
| 700 | 1 | |a Krauss, Ronald M |e verfasserin |4 aut | |
| 700 | 1 | |a Mechanick, Jeffrey I |e verfasserin |4 aut | |
| 700 | 1 | |a Rosenblit, Paul D |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Donald A |e verfasserin |4 aut | |
| 700 | 1 | |a Wyne, Kathleen L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists |d 1995 |g 26(2020), 10 vom: 01. Okt., Seite 1196-1224 |w (DE-627)NLM095479376 |x 1530-891X |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2020 |g number:10 |g day:01 |g month:10 |g pages:1196-1224 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4158/CS-2020-0490 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2020 |e 10 |b 01 |c 10 |h 1196-1224 | ||